Research and Markets: PharmaHandbook 6th Edition: a Guide to the International Pharmaceutical Industry - Volume 2, Emerging Markets

* Reuters is not responsible for the content in this press release.

Thu Aug 27, 2009 11:00am EDT

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/ee4801/pharmahandbook_6th) has
announced the addition of the "PharmaHandbook 6th Edition: A Guide to the
International Pharmaceutical Industry - Volume 2, Emerging Markets" report to
their offering. 

The prescription drug industry is among the most globalized and the most heavily
regulated - in the world. PharmaHandbook is an essential resource for anyone
required to navigate the complexities of the global pharmaceutical marketplace. 

Our customers have called PharmaHandbook "invaluable", "extremely useful", "a
wonderful resource" and say they "look forward to receiving it every year." 

In previous editions PharmaHandbook has been a single volume publication
containing analysis of 40 global markets; however, after careful consideration
and discussions with a number of customers, VOI has decided to break
PharmaHandbook 2009 (sixth edition) into two separate volumes. The volumes will
breakdown along the lines of Developed Markets and Emerging Markets 

Other licensing options are available, please contact customer services for more
information 

Key Topics Covered:

Emerging Markets - Volume II (August, 2009) 

Asia Pacific

* China 
* India 
* Indonesia 
* Taiwan 
* Thailand 
* Vietnam

EU 

EU General

* Czech Republic 
* Hungary 
* Poland 
* Romania

Europe-Non EU

* Russia

Latin America

* Argentina 
* Brazil 
* Chile 
* Mexico 
* Venezuela

ME / Africa

* Egypt 
* Turkey 
* South Africa

For more information visit
http://www.researchandmarkets.com/research/ee4801/pharmahandbook_6th





Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716 

Copyright Business Wire 2009

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.